MAPT and Alzheimer disease: For this purpose, we employed in vitro BBB model and subjected to treatment with in vitro prepared oligomeric tau (truncated tau aa 151-391/4R, 25 kDa), and insoluble PHF-tau isolated from transgenic rat model and human AD brain.